Dec 20, 2019
NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study
Dec 16, 2019
NeuroVive Announces Settlement in Dispute With CicloMulsion AG
Nov 20, 2019
NeuroVive Pharmaceutical AB Interim Report January - September 2019
Aug 21, 2019
NeuroVive Pharmaceutical AB Interim Report January - June 2019
Aug 20, 2019
Save the Date: NeuroVive to host Capital Markets Day in Stockholm on 9 October, 2019
Mar 25, 2019
NeuroVive Pharmaceutical AB Publishes 2018 Annual Report
Mar 19, 2019
NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study
Nov 15, 2018
NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders
Oct 10, 2018
NeuroVive Receives KL1333 Clinical Trial Regulatory Approval
Oct 04, 2018
NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI
Sep 06, 2018
NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan
Aug 28, 2018
NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia
Aug 21, 2018
NeuroVive Pharmaceutical AB Interim Report January - June 2018
Jun 18, 2018
NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics
May 31, 2018
Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)
May 22, 2018
NeuroVive Pharmaceutical AB Interim Report January - March 2018
May 21, 2018
NeuroVive and Yungjin Reports Positive KL1333 Phase I Clinical Study Results Paving the way for Further Clinical Development
May 02, 2018
NeuroVive Initiates Collaboration With Leading US TBI Research Organization
Apr 20, 2018
NeuroVive Presents NVP025 Mitochondrial Myopathy Project Progress at Mitochondrial Medicine Conference
Apr 20, 2018
NeuroVive's Board Members, Senior Executives and Employees Will Subscribe Units in the Ongoing Rights Issue